The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | High economic burden for progressive multiple myeloma: considering costs
Rafael Fonseca
• 1 Dec 2018
The progression of multiple myeloma has been found to pose a significant economic burden. Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, and urges the medical community to consider the long-term, with more expensive treatments potentially giving greater disease control and durable remission further downstream.
